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Monocytes can mediate the clinical response of granulocyte
macrophage colony-stimulating factor (GM-CSF) in colitis.
GM-CSF-activated monocytes express adenosine triphos-
phate–converting enzymes (CD39/CD73) to generate aden-
osine which possibly induces regulatory T cells. This
mechanism of monocytes may control intestinal
inﬂammation.
BACKGROUND & AIMS: Granulocyte macrophage colony-
stimulating factor (GM-CSF) treatment induces clinical
response in patients with active Crohn’s disease. To explore
whether monocytes mediate GM-CSF effects in vivo, we used a
mouse model of chronic colitis induced by dextran sulfate so-
dium (DSS).
METHODS: Murine bone marrow-derived monocytes were
activated with GM-CSF in vitro, and gene expression, pheno-
type, and function of GM-CSF-activated monocytes (GMaM)
were analyzed. Therapeutic effects of GMaM were assessed in a
model of chronic colitis induced by repeated cycles of DSS.
Monocytes were administered intravenously and their immu-
nomodulatory functions were evaluated in vivo by clinical
monitoring, histology, endoscopy, immunohistochemistry, and
expression of inﬂammatory markers in the colon. The distri-
bution of injected monocytes in the intestine was measured by
in vivo imaging.
RESULTS: GMaM expressed signiﬁcantly higher levels of anti-
inﬂammatory molecules. Production of reactive oxygen species
was also increased while phagocytosis and adherence were
decreased. GMaM up-regulated CD39 and CD73, which allows the
conversion of adenosine triphosphate into adenosine and coin-
cided with the induction of Foxp3þ (forkhead-box-protein P3
positive) regulatory T cells (Treg) in cocultures of GMaM and
naive T cells. In chronic DSS-induced colitis, adoptive transfer of
GMaM led to signiﬁcant clinical improvement, as demonstrated
by reduced weight loss, inﬂammatory inﬁltration, ulceration, and
colon shrinkage. As GMaMmigrated faster and persisted longer in
the inﬂamed intestine compared with control monocytes, their
presence induced Treg generation in vivo.CONCLUSIONS: GM-CSF leads to speciﬁc monocyte activation
that modulates experimental colitis via mechanisms that include
the induction of Treg. We demonstrate a possible mechanism of
Treg induction through CD39 and CD73 expression on mono-
cytes. (Cell Mol Gastroenterol Hepatol 2015;1:433–449; http://
dx.doi.org/10.1016/j.jcmgh.2015.04.005)
Keywords: Adaptive Immunity; Dextran Sulfate Sodium;
Experimental Colitis; Immune Response; Innate Immunity; GM-
CSF; Monocyte; T Cell.
rohn’s disease (CD) is a chronic inﬂammatory bowelCdisease (IBD) that may affect the whole gastroin-
testinal tract. It was initially hypothesized that the inﬂam-
matory pathology in CD was exclusively a result of
dysregulated adaptive immune responses (eg, T cells).1
However, more recent data implicate roles for innate as
well as adaptive immunity in CD pathogenesis,2,3 supported
by the discovery of genetic defects associated with innate
immune functions (eg, mutations in nucleotide-binding
oligomerization domain-containing protein 2) in CD pa-
tients.4 Further support comes from the observation that
monocyte/macrophages of some CD patients fail to secrete
proinﬂammatory cytokines and chemokines.5,6 Therefore,
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source of macrophages and dendritic cells (DCs) in inﬂamed
intestinal mucosa,7 play key roles in CD pathogenesis.
Monocytes and their derivatives are crucial for most
phases of immune reactions, ranging from the progression
to resolution of inﬂammatory lesions. This functional di-
versity reﬂects the phenotypic heterogeneity of monocytes
and macrophages, encompassing classic proinﬂammatory
monocyte/macrophages (M1-polarized) to alternatively
activated macrophages (M2-polarized) generated by expo-
sure to interleukin 4 (IL-4)/IL-13. In addition, it is known
that regulatory monocytes and macrophages that produce
IL-10 or transforming growth factor-b are generated in
response to glucocorticoids or interferon-g alone.8,9 Ad-
vances in our understanding of how CD can result from an
altered innate immune function have led to new therapeutic
approaches that enhance innate immunity and host defense.
Stimulators of innate immunity have been tested,
including granulocyte macrophage colony-stimulating factor
(GM-CSF), a classic growth factor for innate immune cells of
the myeloid lineage.10 GM-CSF therapy has been observed to
provide partial protection against intestinal inﬂammation in
a mouse dextran sulfate sodium (DSS) colitis model,11,12 and
GM-CSF–deﬁcient mice show increased susceptibility to
DSS-induced colitis.13 Mechanisms by which GM-CSF exerts
beneﬁcial effects in CD have not been fully elucidated, but
they likely involve key mediators of innate and adaptive
immunity, possibly including forkhead-box-protein P3 pos-
itive (Foxp3þ) regulatory T cells (Treg) recruitment via
CD11bþCD103þ DCs.14,15
Interestingly, GM-CSF injection into mice with DSS-
induced colitis results in an accumulation of splenic
CD11bþ cells that promote wound closure and epithelial cell
proliferation in vitro. Furthermore, transfer of in vivo GM-
CSF-expanded splenic CD11bþ cells into DSS-treated mice
signiﬁcantly reduces disease severity.11 It remains to be
shown however, how the expansion of GM-CSF-activated
monocytes (GMaM) leads to beneﬁcial effects in IBD.
Because of the central role of different monocyte sub-
types and their derivative cells in the immune system, we
hypothesized that the effects of GM-CSF on mucosal
inﬂammation could be mediated via monocytes. Therefore,
we activated bone marrow-derived monocytes with GM-CSF,
characterized their phenotype, and examined their func-
tional properties in vitro. The therapeutic potential of the
GMaM was assessed in a DSS-induced model of chronic
colitis and veriﬁed in the T-cell transfer colitis model. We
show that GMaM are both gut homing and strong inhibitors
of DSS-induced colitis, most likely by inducing Treg that are
generated in high numbers by GMaM in vitro when cocul-
tured with naive T cells. Furthermore, GM-CSF mediates up-
regulation of E-NTPDase (CD39) and ecto-50-nucleotidase
(CD73) on GMaM, which is associated with enhanced con-
version of adenosine triphosphate (ATP) to adenosine and is
likely used for the observed induction of Treg. Our ﬁndings
suggest that GMaM use CD39 and CD73 to differentiate Treg
from naive T cells, which combined with other unique
immunomodulatory features of GMaM can lead to amelio-
ration of excessive intestinal inﬂammation.Materials and Methods
Mice
The B6.129P(Cg)-Ptprca Cx3cr1tm1Litt/LittJ, Rag1/,
CD45.1 (C57/BL6-Ly 5.1), and corresponding wild-type
(WT) C57BL/6J mice were obtained from the Jackson Lab-
oratory (Bar Harbor, ME). The CD39/ mice were kindly
provided by Prof. Kettenmann from the Max-Delbrueck-
Center, Berlin, Germany. All mice were housed and bred
under speciﬁc pathogen-free conditions and were used be-
tween 8 and 14 weeks of age. All animal studies were
performed in accordance to approved protocols of the ani-
mal welfare committee of the North Rhine-Westphalia State
Agency for Nature, Environment, and Consumer Protection,
Recklinghausen, Germany (LANUV NRW Reference No. 87-
51.04.2010.A113).Isolation of Bone Marrow-Derived Monocytes
and In Vitro GM-CSF Treatment
Bone marrow-derived monocytes and GMaM were
generated in vitro from freshly isolated bone marrow pre-
cursor cells. Brieﬂy, femurs and tibias were dissected from
mice, tissue cleaned off, then ﬂushed with cold phosphate-
buffered saline (PBS)/1% fetal calf serum (FCS). Erythro-
cytes were removed by incubation in tris ammonium
chloride buffer, and the cells further separated on a Ficoll
gradient (Biochrom, Berlin, Germany). The interphase was
collected, and the remaining T cells (CD90þ), B cells
(CD19þ), and DCs (CD11cþ) were removed using magnetic
beads coupled to anti-CD90, anti-CD19, and anti-CD11c
antibodies using magnetic-activated cell sorting (MACS)
technology according to the manufacturer’s instructions
(Miltenyi Biotech, Bergisch Gladbach, Germany). The
remaining cells were cultured for 2 days in 20% L929 cell
supernatant (containing M-CSF) conditioned Dulbecco’s
modiﬁed Eagle medium containing 2 mM glutamine, 0.1 mM
nonessential amino acids (all Invitrogen, Karlsruhe, Ger-
many), penicillin (100 U/mL), streptomycin (100 mg/mL),
and 10% heat-inactivated FCS (all Biochrom) including
additional supplementation with 150 U/mL recombinant
murine GM-CSF (ImmunoTools, Friesoythe, Germany) for
induction of GMaM.Induction of Colitis and Treatment
Mice were fed with 2% (wt/vol) DSS (molecular weight
36–50 kDa; MP Biomedicals, Santa Ana, CA) dissolved in UV-
sterilized tap water ad libitum for 3 days, followed by 4 days
of untreated tap water alone. The treatment cycle was
repeated twice subsequently (three cycles in total). Non-
DSS-treated control animals received tap water alone
throughout the experiment. GMaM or control monocytes
(2  106 cells) were administered intravenously 1 day
before starting the third DSS treatment cycle.
For induction of transfer colitis, syngeneic CD4þ T cells
were prepared from spleens of C57BL/6 mice, and CD25þ
cells were removed using MACS technology. We adoptively
transferred 1  106 CD4þCD25 T-cells into Rag1/ mice
(on C57BL/6 background) intravenously. The weight of the
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until they lost body weight on consecutive days and colitis
had been established. All animals that fulﬁlled the criterion
of fully developed colitis by days 19–22 were intravenously
injected with 2  106 monocytes per mouse (GMaM or
control monocytes), and their weight was monitored for
additional 10 days.In Vivo Induction of Regulatory T Cells by GMaM
We injected Rag1/ mice (on C57BL/6 background)
with 2  106 CD4þ T cells (intravenous) to reconstitute
the T-cell pool; to some mice, 2  106 GMaM or control
monocytes (WT or CD39/) were simultaneously injec-
ted (intravenous). After 7 days, the spleens were
removed, a single-cell suspension was prepared, and the
cells were counted. Afterward, the presence of Foxp3þ
CD4þ T cells was evaluated by ﬂow cytometry as
described in the ﬂow cytometry section. Finally, the total
Treg cell number was calculated based on number of total
splenocytes.Assessment of Colon Inﬂammation
and Colonoscopy
Mice were weighed daily and were visually inspected for
hunched posture, diarrhea, and rectal bleeding. On day 20,
mice from each group were anesthetized with isoﬂurane
(100% v/v, 1.5 vol. %, 1.5 L/min) (Florene; Abbott, Wies-
baden, Germany) and were given an enema (Freka-Clyss;
Fresenius Kabi, Sèvres, France).
High-resolution colonoscopy was performed using a
veterinary endoscopy workstation (Coloview; Karl Storz,
Tuttlingen, Germany) to assess colitis. Under visual control,
the rigid miniature endoscope (1.9-mm outer diameter) was
inserted according to anatomic conditions. The modiﬁed
murine endoscopic index of colitis severity (MEICS), which
evaluates thickening of the colon, changing vascularity, and
the presence of ﬁbrin, granular mucosal surfaces, and also
stool consistency (0–3 points each, maximum of 15 points),
was used to investigate colonic inﬂammation.16
To measure colon length, the colon was excised between
the ileocecal junction and proximal rectum and was
measured with a ruler without stretching the organ. Sub-
sequently, the colon was rinsed with ice-cold PBS and cut
open longitudinally. A specimen of the distal colon was
taken and immediately frozen in liquid nitrogen. The
remaining colon was embedded for cryosectioning in a
“swiss roll” conﬁguration.17Quantitative Real-Time Polymerase
Chain Reaction
Gene expression analysis in mouse monocytes after
treatment with GM-CSF for 48 hours was performed by
quantitative real-time reverse-transcription polymerase
chain reaction (qRT-PCR) as described previously else-
where.18 The total RNA was isolated from distal colon tissue
using a Precellys24 (Bertin Technologies, Montigny-le-
Bretonneux, France) and a NucleoSpin RNA II Kit(Macherey-Nagel, Düren, Germany) according to the manu-
facturer’s instructions. We performed PCR ampliﬁcations on
a CFX384 Touch real-time PCR detection system (Bio-Rad
Laboratories, Munich, Germany). Relative gene expression
was normalized to the endogenous housekeeping control
gene ribosomal protein L13a, and the relative expression of
respective genes was calculated by the comparative
threshold cycle method. The primers used for qRT-PCR
analysis are given in Supplementary Table 1.Flow Cytometry
A FACSCanto Flow Cytometer (BD Biosciences, Heidel-
berg, Germany) was used for ﬂow cytometry measure-
ments, and the analysis was performed using FlowJo
software (version 9.7; TreeStar, Ashland, OR). Antibody
staining of cells was routinely performed with 1 mg/mL of
each antibody. For detection of cell-surface molecules, ﬂow
cytometry was performed as described elswhere.19 For
coculture experiments, intracellular staining of Foxp3
expression was performed using the Foxp3/Transcription
Factor Staining Buffer Set (eBioscience, San Diego, CA) ac-
cording to the manufacturer’s instructions. The monoclonal
antibodies used for surface and intracellular staining are
given in Supplementary Table 2. The expression of CX3CR1
on monocytes was evaluated using reporter mice that ex-
press a green ﬂuorescent protein under transcriptional
control of the CX3CR1 promoter (B6.129P(Cg)-Ptprca
Cx3cr1tm1Litt/LittJ).Phagocytosis, Adhesion, and Oxidative Burst
For evaluation of phagocytic capacity, WT or CD39/
GMaM and control monocytes were incubated with
carboxylate-modiﬁed polystyrene ﬂuorescent yellow-green
beads (Sigma-Aldrich, Taufkirchen, Germany) for 4 hours
at a 1:10 ratio of monocytes to beads. Phagocytosis rates
were determined by ﬂow cytometry.
For determination of cell adhesion, either control
monocytes or GMaM (2  105) were seeded in triplicates
into 96-well ﬂat-bottom plastic tissue culture plates and
incubated at 37C and 5% CO2 for 4 hours. Nonadhering
cells were removed by washing twice. Remaining adherent
cells were ﬁxed with 2% glutaraldehyde (Sigma-Aldrich) for
10 minutes, washed twice with distilled H2O, and stained
with 0.5% crystal violet (Merck Millipore, Darmstadt, Ger-
many) in 2% ethanol (pH 6.0) for 15 minutes at room
temperature. The cells were washed three times and lysed
by adding 10% acetic acid, and the optical density (OD) at
560 nm was determined using an Asys Expert 96 Microplate
Enzyme-Linked Immunosorbent Assay reader (Anthos
Mikrosysteme, Krefeld, Germany).
For the determination of reactive oxygen species (ROS),
monocytes were stimulated for 4 hours at 37C with
Escherichia coli 055:B5–derived lipopolysaccharide (LPS)
(10 ng/mL; Sigma-Aldrich) in the presence of 15 mM dihy-
drorhodamine 123 (Merck, Darmstadt, Germany) for the
ﬁnal 15 minutes. Stimulated monocytes were then analyzed
by ﬂow cytometry.
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Cytokine secretion of WT or CD39/ GMaM and control
monocytes after 16 hours of LPS treatment (100 ng/mL;
Sigma-Aldrich) was measured from cell culture superna-
tants. Murine tumor necrosis factor a (TNFa), IL-1b, IL-6,
and IL-10 were measured by using a bead-based multiplex
assay (mouse TH1/TH2 10plex FlowCytomix; eBioscience)
according to the manufacturer’s instructions.
Aldehyde Dehydrogenase, Arginase Activity, and
Nitrite Assay
To indirectly calculate the production of the vitamin A
metabolite, retinoic acid (RA), in GMaM and control mono-
cytes, aldehyde dehydrogenase (ALDH) activity was
measured with a commercially available ALDEFLUOR
detection kit (StemCell Technologies, Vancouver, BC, Can-
ada) according to the manufacturer’s protocol. Dead cells
were excluded by counterstaining with 5 mL of
7-aminoactinomycin D (Biolegend, San Diego, CA).
Arginase activity was evaluated by measuring the
conversion of arginine to ornithine and detectable urea in
cell lysates of GMaM and control monocytes using an
arginase assay kit (Abnova, Walnut, CA). In brief, we lysed
1  106 cells in 100 mL of 10 mM Tris-HCl (pH 7.4) con-
taining proteinase inhibitors and 0.4% Triton X-100.
Lysates were centrifuged for 10 minutes at 4C at 14,000g,
and 40 mL of supernatants mixed with 10 mL 5X substrate
buffer were transferred in a 96-well ﬂat-bottom plate and
incubated for 2 hours at 37C. The reaction was stopped
by adding 200 mL of urea reagent (kit component) to all
wells. The plate was incubated at room temperature for 1
hour, and urea production was determined by measuring
the OD at 430 nm.
To measure basal nitric oxide (NO) production in su-
pernatants of WT or CD39/ GMaM and control monocytes
after 48 hours of culture, we used the Griess reagent system
(Promega, Fitchburg, WI) according to the manufacturer’s
protocol. We read the OD at 550 nm with a spectropho-
tometer. The sample nitrite concentration was calculated
from a nitrite standard reference curve.
Coculture and Inhibitors
Naïve T cells were isolated from C57Bl/6J splenocytes
using the pan T cell kit II (Miltenyi Biotec) according to the
manufacturer’s protocol and were cocultured with respec-
tive monocytes at 37C and 5% CO2 in RPMI 1640 supple-
mented with 10% FCS, penicillin (100 U/mL), streptomycin
(100 mg/mL), 15 mM HEPES (pH 7.4), 2 mM L-glutamine,
and 1% nonessential amino acids. We applied 1  105
splenic T cells to each well (96-well plate), and 2  104
GMaM or control monocytes were added (ratio of 5:1 for T
cells/monocytes, triplicates for each condition) and incu-
bated for 5 days without further T-cell stimulation. For
detecting cell proliferation, we labeled T cells with carbox-
yﬂuorescein succinimidyl ester (CFSE) (eBioscience). The
CFSE was diluted to a working concentration of 500 nM in
PBS, with a 100-mL CFSE working solution used for 1  106
cells. The T cells were stained for 4 minutes at roomtemperature and subsequently were washed twice with
PBS/1% FCS. The staining efﬁciency of CFSE was routinely
controlled by ﬂow cytometry.
To inhibit CD39 and/or CD73, 200 mM ARL 67156 tri-
sodium salt and/or a,b-methyleneosine 50-diphosphate so-
dium salt (Merck Millipore), respectively, were used. For
evaluation of CD39 blocking efﬁcacy, 10mM adenosine
(Sigma-Aldrich) was added. In addition, 50 mM or 100 mM
Nu-hydroxy-nor-L-arginine (Sigma-Aldrich) was used to
inhibit arginase activity. To block IL-10-mediated effects,
5 mg/mL anti-IL-10 (clone: JES5–16E3) or 5 mg/mL anti-
IL-10 receptor (clone: 1B1.3a) antibodies (both Biolegend)
were used.
Immunohistochemistry
Cryosections (5 mm) were prepared from Cryo-OCT
(Tissue-Tek; Fisher Scientiﬁc, Schwerte, Germany)
embedded colon tissue. After the slides had been ﬁxed for
10 minutes, we stained them with H&E. The sections were
independently evaluated by two blinded investigators using
a scoring system to grade inﬂammation and cell inﬁltration
from 0 to 3 (0 ¼ none; 1 ¼ mild; 2 ¼ moderate; 3 ¼ severe)
and the occurrence of ulcerations from 0 to 3 (0¼ none; 1 ¼
ulcers spanning up to two crypts; 2 ¼ ulcers spanning 3 to
10 crypts; 3 ¼ ulcers spanning more than 10 crypts). The
grading was performed for the proximal and the distal part
of the colon separately, with a combined maximal grading
score of 12. For the staining of inﬁltrating phagocytes, a
monoclonal antibody raised against CD11b (clone: M1/70;
BD Biosciences) was used, and the presence of regulatory T
cells was evaluated using a monoclonal antibody against
Foxp3 (clone: MF-14; Biolegend). Secondary antibody
binding and subsequent peroxidase reaction was performed
as described previously.20
In Vivo Cell Tracking
For in vivo cell tracking, monocytes were stained with
a commercially available lipophilic tracer 1,1-dioctadecyl-
3,3,3,3-tetramethylindotricarbocyanine iodide (Life Tech-
nologies, Darmstadt, Germany) with an emission
maximum of 782 nm as described elsewhere.21 In vivo
distribution of labeled cells across the intestine was
studied 48 hours and 96 hours after intravenous injection
using a planar small animal ﬂuorescence-mediated to-
mography system (FMT 2500; VisEn Medical, Bedford,
MA) as described elsewhere.21 Ex vivo optical imaging of
the dissected intestine placed on a petri dish 96 hours
after intravenous injection was performed using a whole-
body multichannel small animal ﬂuorescence reﬂectance
imager (in vivo FX Pro; Bruker, Billerica, MA). The
monocyte migration toward Peyer’s patches was statisti-
cally analyzed by ﬁrst selecting the regions of interest,
which were Peyer’s patches observed in white-light im-
ages. These images were then overlaid with corresponding
ﬂuorescence images, and the mean ﬂuorescent intensities
evaluated from these regions of interest. Mice that
received unlabeled monocytes served as the control for
autoﬂuorescence discrimination.
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Lamina Propria
Migratory capacity of WT or CD39/ control monocytes
and GMaM was assessed in CD45.1 (on C57BL/6 back-
ground) mice with chronic DSS-induced colitis. One day
before the start of the third DSS-treatment cycle, mice
received either CD45.2 WT control monocytes, WT GMaM,
CD39/ control monocytes, or CD39/ GMaM (2  106
each). Two days after injection, lamina propria mononuclear
cells from the colon were isolated using the Lamina Propria
Dissociation Kit and a GentleMACS Octo Dissociator (both
Miltenyi Biotech) according to the manufacturer’s protocol.
Inﬁltrating CD45.2-positive cells were stained and
measured by ﬂow cytometry as described earlier.
Statistics
Data are expressed as mean ± standard error of the
mean (SEM) and were tested for statistical signiﬁcance us-
ing the Student t-test and one-way or two-way analysis of
variance (ANOVA) with Bonferroni correction as indicated.
P < .05 was considered statistically signiﬁcant. All calcula-
tions were performed using Prism version 6 for Macintosh
(GraphPad Software, San Diego, CA).
Results
GM-CSF-Activated Monocytes Are
Phenotypically Distinct Monocytes
Activated monocytes were generated from bone marrow
precursor cells of C57Bl/6 mice by GM-CSF treatment for 48
hours. GMaM were analyzed by ﬂow cytometry for several
surface molecules known to be expressed on monocyte
subsets and implicated for further development into
specialized macrophages ranging from M1-polarized to M2-
polarized. We found E-NTPDase (CD39), ecto-50-nucleo-
tidase (CD73), and the IL-1 decoy receptor (CD121b) highly
up-regulated after GM-CSF activation. The fractalkine re-
ceptor (CX3CR1) that is expressed by alternatively activated
monocytes (rolling monocytes) that can give rise to M2-
polarized macrophages22 was down-regulated on
Ly6cþCD11bþ monocytes (Figure 1A). The costimulatory
molecules CD80 (Figure 1A), CD86, MHCII, and B7-H1 (see
Figure 1E) were highly up-regulated on GMaM. Expression
of cell surface markers was conﬁrmed by mRNA expression
analysis, except for CD39 mRNA, which was not differen-
tially expressed after 48 hours of GM-CSF activation
compared with untreated monocytes (see Figure 1B) but
earlier after 4, 16, and 24 hours (see Figure 1D).
We performed additional qRT-PCR experiments to
further investigate effects of GM-CSF on activation and po-
larization in monocytes. We found increased expression of
arginase 1 (Arg1), IL-1b, and also the IL-1b counter-
regulating IL-1 receptor antagonist (IL-1Ra) in GMaM (see
Figure 1C). Interestingly, M2 polarization marker genes
were discordantly expressed. For example, found in in-
ﬂammatory zone 1 (FIZZ1) and chitinase-3-like-3 (YM1)
were increased, whereas the mannose receptor (CD206)
and scavenger receptor CD163 were decreased. The tran-
scription factor Interferon regulatory factor 4 (IRF4),previously implicated in M2 polarization,23 was not differ-
entially expressed (see Figure 1C). Although GMaM share
markers of both classic and nonclassic monocytes and their
derivative macrophages, their phenotype does not
completely match either of these monocyte subsets
described in the literature. Therefore, we consider GMaM to
be monocytes in a unique and distinct state of activation.
GM-CSF Treatment Modulates
Monocyte Functions
Monocytes play key roles in ﬁghting foreign particles via
phagocytosis or production of ROS but also in activation and
regulation of cells of the adaptive immune system, either by
secretion of cytokines or by cell contact–mediated mecha-
nisms. We therefore investigated whether GM-CSF might
modify the activity of monocytes in either of these capac-
ities. Adherence of GMaM to plastic culture plates and their
phagocytic activities were signiﬁcantly reduced compared
with untreated monocytes (Figure 2A). Importantly, ROS
formation and thus the capacity to kill pathogens was
signiﬁcantly enhanced in GMaM (see Figure 2A). Conversely,
RA production, as determined by ALDH activity, was slightly
diminished in GMaM (see Figure 2A). We found Arg1 ac-
tivity signiﬁcantly increased in GMaM; because NO synthase
and Arg1 compete for the same substrate (L-arginine), NO
production was also strongly reduced (see Figure 2A).
Next, we analyzed the inﬂuence of GM-CSF (treatment
for 48 hours) on cytokine production in response to LPS
stimulation for 16 hours. We observed an increased release
of proinﬂammatory IL-1b, TNFa, and IL-6 from GMaM
compared with control monocytes after LPS stimulation (see
Figure 2B). Interestingly, we also observed an increased
release of anti-inﬂammatory IL-10 (see Figure 2B).
GMaM Have a Therapeutic Effect in
DSS-Induced Colitis
After we had evaluated the speciﬁc activation pattern of
GMaM in vitro, because monocytes represent the exclusive
source of intestinal macrophages we tested the in vivo
therapeutic potential of GMaM in a mouse colitis model. We
chose the chronic DSS-induced colitis model because it
mimics many of the pathologic features of CD (eg, epithelial
degradation and bacterial invasion) and thereby allows
testing for GMaM-mediated effects that may alter intestinal
macrophage function. Colitis was induced by repetitive
administration of DSS in drinking water, with disease
severity primarily assessed by monitoring body weight loss.
We observed signiﬁcant weight loss in untreated mice
and mice treated with control monocytes (Figure 3A). In
striking contrast, GMaM-treated mice showed no weight loss
after DSS exposure (see Figure 3A, ﬁlled circle) and generally
displayed better disease outcomes when taking behavior,
hunched posture, diarrhea, and rectal bleeding into account
(data not shown). This observation was supported by the
ﬁndings of signiﬁcantly less colon shrinkage (see Figure 3B,
black bar) and signiﬁcantly lower MEICS scores (see
Figure 3C, black bar) as assessed by colonoscopy (see
Figure 3F, example pictures). The GMaM-treated mice also
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Figure 1. Granulocyte macrophage colony-stimulating factor (GM-CSF)-activated monocytes have a distinct pheno-
type. Bone marrow-derived control monocytes and GM-CSF-activated monocytes (GMaM) were generated in vitro for 48
hours. (A) Resulting cells were stained for cell-surface molecules and analyzed by ﬂow cytometry. Expression is shown as
representative dot plots gated on CD11bþ cells, showing Ly6c expression (y axis) versus respective cell surface molecules (x
axis). (B) Expression of cell surface molecules was validated using quantitative reverse-transcription polymerase chain reaction
(qRT-PCR) (n ¼ 5–6). (C) The mRNA levels of several monocyte subset deﬁning molecules were investigated by qRT-PCR (n ¼
5–6). (D) Time-dependent expression of CD39 mRNA in GMaM using qRT-PCR shown as n-fold expression compared with
control monocytes (n ¼ 3). (E) Representative dot plots of costimulatory molecules gated on CD11bþ cells show Ly6c
expression (y axis) versus respective cell surface molecules (x axis). (B–D) Graphs show mean values (± standard error of the
mean), and statistical signiﬁcance was determined by unpaired Student t test. *P < .05; **P < .01; ***P < .001.
438 Weinhage et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4showed signiﬁcantly lower IL-1b and TNFa mRNA levels in
the distal colon after DSS exposure than the mice receiving
control monocytes (see Figure 3D). Furthermore, GMaM
treatment led to signiﬁcantly reduced intestinal inﬂamma-
tion as indicated by reduced prevalence of CD11bþ phago-
cytes (eg, neutrophils), moderate colonic wall thickening,
less goblet cell loss (see Figure 3G), and lower histopathol-
ogy score values compared with controls (see Figure 3E).
Together, these results demonstrate a clear therapeutic
beneﬁt of GMaM delivery in an in vivo colitis model.GMaM Inﬁltrate the Intestine in Higher Numbers
Compared With Control Monocytes
To address whether the beneﬁcial effects of GMaM
treatment are a direct effect of the transferred monocytes,
we investigated the in vivo migratory potential of GMaM
within the context of chronic DSS-induced colitis (Figure 4).
We speciﬁcally aimed to show that GMaM migrate to the siteof inﬂammation, thus supporting a direct mechanistic role
for their amelioration of colitis severity.
In performing ﬂow cytometry–based staining of gut
homing molecules on monocytes (eg, a4b7, CCR7, CCR9,
CD103), we found CCR2, necessary for migration toward
inﬂammatory sites,24 and CCR6, used for the migration to-
ward lymph follicles such as Peyer’s patches,25 to be up-
regulated on GMaM (Figure 4A). CCR7, CCR9, CD103, and
a4b7, however, were not regulated on GMaM compared
with the control monocytes.
When GMaM or control monocytes were labeled with a
near infrared ﬂuorescent dye and injected intravenously 1
day before the last DSS treatment cycle, the GMaM were
signiﬁcantly enriched in the intestine relative to the control
monocytes at 48 hours after injection. This effect was more
pronounced after 96 hours when, by contrast, the control
monocytes were mostly absent (Figure 4B and
Supplementary Video 1, GMaM 48 hours after injection and
Supplementary Video 2, monocytes 48 hours after injection).
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Figure 2. Granulocyte macrophage colony-stimulating factor (GM-CSF) treatment modulates monocyte functions. (A)
Upper left/middle panel: Potential of granulocyte-macrophage colony-stimulating factor–activated monocytes (GMaM) and
control monocytes to adhere to plastic surfaces and phagocytosis of latex beads (n ¼ 5). Upper right panel: Reactive oxygen
species (ROS) production of GMaM and control monocytes as rhodamine positive cells (n ¼ 11). Lower left panel: To indirectly
estimate the production of retinoic acid (RA), aldehyde dehydrogenase (ALDH) activity measured using Aldeﬂuor and displayed
as the percentage of Aldeﬂuor-positive cells (n ¼ 4). Lower middle panel: Nitrite oxide (NO) production in cell culture super-
natants of GMaM compared with control monocytes (n ¼ 3). Lower right panel: Arginase activity evaluated by measuring the
conversion of arginine to ornithine and detectable urea in cell lysates (n ¼ 3). (B) Cytokine secretion of GMaM and control
monocytes after lipopolysaccharide treatment measured in cell culture supernatants (n ¼ 3). Statistical signiﬁcance was
determined by unpaired Student t test. *P < .05; **P < .01; ***P < .001; n.s., not statistically signiﬁcant.
July 2015 GM-CSF-Activated Monocytes Ameliorate DSS Colitis 439To allow a more detailed view of the GMaM inﬁltration sites,
we removed the intestine after 96 hours to study the
monocyte inﬁltration by ﬂuorescence reﬂectance imager
technology (see Figure 4C). We observed signiﬁcantly more
inﬁltration of GMaM into Peyer’s patches (arrows) than un-
treated control monocytes (see Figure 4C and D).
Thus, we show that GMaM not only migrate faster to the
inﬂamed tissue compared with control monocytes but
persist within the tissue for signiﬁcantly longer periods.
These results reveal preferential homing of GMaM to sites of
intestinal inﬂammation, which coincides with expression of
CCR2 and CCR6 and directly correlates with improved dis-
ease outcome in the DSS colitis model.Foxp3þ T-Cell Induction by GMaM Is
Required for Therapeutic Effectiveness in
DSS-induced Colitis
From the in vivo cell tracking studies it was apparent
that GMaM directly migrate toward secondary lymphaticorgans such as Peyer’s patches. Therefore, we asked
whether GMaM might exert their protective inﬂuence via
interactions with other immune cell types. Accordingly, we
performed immunostaining for a range of immune markers
in colon cryosections of DSS-treated mice injected with
either GMaM or control monocytes. Interestingly, compared
with all other groups, we found that Foxp3-expressing Treg
were signiﬁcantly enriched in the lymph follicles of mice
that received GMaM (Figure 5A and B). In addition, an
increased presence of Foxp3þ cells (red staining) was only
found in the lymph follicles, not in the lamina propria (see
Figure 5A).
We tested the requirement for Treg in GMaM-mediated
protection against colitis in Rag1/ homozygous null mice,
which lack all mature adaptive immune cells including func-
tional T-cell subsets. GMaM injection was not protective
against DSS-induced colitis in Rag1/ mice as evidenced by
their increased body weight loss and colon shrinkage (see
Figure 5C and D). In comparison with our earlier observations
in WT mice injected with GMaM (see Figure 3A), our results
440 Weinhage et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4show that adaptive immunity is highly required for GMaM-
mediated protection against colitis and provide evidence to
support a mechanistic role for Foxp3-expressing Tregs.GMaM Showed Beneﬁcial Effects in T-Cell
Transfer Colitis and Led to an Increased Number
of Splenic Regulatory T Cells In Vivo
To further investigate the crosstalk between innate
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July 2015 GM-CSF-Activated Monocytes Ameliorate DSS Colitis 441monocytes or GMaM intravenously into Rag1/ mice. After
1 week we isolated the spleen of these mice. Here we could
show in vivo an increased total cell number of Foxp3þ CD4þ
T cells in splenocytes of Rag1/ mice, which together with
CD4þ T cells received GMaM (see Figure 6C).
GMaM Induce Proliferation and Differentiation of
Foxp3þ CD4þ T Cells via Adenosine/CD39 but
Not Arginase In Vitro
The in vivo experiments found circumstantial evidence
to support a role for Treg in GMaM-induced protection
against colitis. To formally substantiate this, we investigated
whether GMaM can directly promote activation and differ-
entiation of Treg from a naive T-cell pool in vitro. We per-
formed coculture experiments using a 5:1 ratio of naive
splenic T cells to monocytes. We found signiﬁcantly higher
proliferation of CD4þ and CD8þ T cells (Figure 7A and data
not shown) coincubated with GMaM compared with the
untreated monocytes. Additionally we demonstrated that
GMaM could induce Foxp3 expression in Treg in vitro (see
Figure 6B).
Several self-molecules and mediators have been re-
ported to induce Treg differentiation,26,27 including adeno-
sine and arginase.28–30 Interestingly, in our earlier
phenotypic characterization of GMaM we observed
increased expression of CD39 and CD73 (see Figure 1A and
B), both of which play roles in anti-inﬂammatory adenosine
biosynthesis.31 Similarly, we also observed increased
expression and activity of Arg1 (see Figures 1C and 2A).
Taking these observations into account, we examined
whether either or both of these pathways were required for
GMaM-dependent induction of Treg.
Pharmacologic inhibition of either CD39 or CD73
signiﬁcantly reduced GMaM-dependent induction of Foxp3þ
Treg from naive T cells compared with the control cultures
(see Figure 7C). This inhibitory effect was completely
abolished by resubstituting adenosine in CD39 inhibition
experiments. Furthermore, addition of adenosine alone (ie,
incubation without the CD39 inhibitor) even increased
GMaM-mediated Treg induction (see Figure 7D). In contrast,
inhibition of arginase activity and blocking IL-10 or IL-10
receptor had no effect on the ability of GMaM to induce aFigure 3. (See previous page). Granulocyte-macrophage colo
a therapeutic effect in dextran sulfate sodium (DSS)-induced
by repeated oral administration of DSS in C57Bl/6 mice. One d
either control monocytes, GMaM, or phosphate-buffered saline
the percentage of weight change of three independent experime
day 21, colons were removed, and the colon lengths were me
standard error of the mean (SEM). (C) Murine endoscopic index o
resolution colonoscopy. (D) Proinﬂammatory cytokines (interleuk
measured in DSS-treated and healthy control C57Bl/6 mice by q
distal colon biopsies taken at the end of the experiment. Mean ±
group). (E) Colon inﬂammation scores (mean ± SEM) were grade
and the distal part of the colon separately (n ¼ 11). (F) Represen
two independent experiments are shown (arrow shows ﬁbrin
microscopic colon images of mice with colitis and healthy cont
mm). Statistical signiﬁcance was determined by unpaired Studen
of variance with Bonferroni correction was used. *P < .05; **PTreg phenotype under the conditions tested (see Figure 7E
and F). Collectively these results identify GMaM as potent
inducers of Treg via activation of anti-inﬂammatory aden-
osine biosynthesis.CD39 Is Responsible for Selected
GMaM Functions
As we had found CD39 to be necessary for GMaM-
mediated Treg induction, we were also interested in the
role of CD39 in other previously observed GMaM functions.
We repeated some functional assays with CD39/ GMaM
and could show that CD39 only played a role in NO pro-
duction. All other monocyte functions (eg, adhesion,
phagocytosis, ROS and RA production) were comparable
between WT and CD39/ GMaM (Figure 8A).
With regard to LPS-induced cytokine production CD39/
GMaM failed to produce IL-10, whereas an observed GM-
CSF–mediated increased release of IL-1b, TNFa, and IL-6 was
also seen in CD39/ GMaM (see Figure 8B). One striking
feature of GMaM was the higher migratory potential toward
sites of inﬂammation in the intestine.
Taking into account that CD39 has been described to be
involved in migration of monocytes32 we performed in vivo
migration experiments with CD39/ GMaM. To be able to
distinguish between donor and recipient cells, we used
CD45.2-expressing GMaM (WT and CD39/) and trans-
ferred them into CD45.1 recipient mice that were induced to
develop colitis using DSS. Chronic colitis was induced ac-
cording to the standard DSS-treatment regime (three cycles
DSS dissolved in tap water ad libitum for 3 days, followed by
4 days of untreated tap water alone) in CD45.1 mice. The
CD45.2 expressing CD39/ or WT monocytes were injected
into CD45.1 recipients; 2 days later colonic lamina propria
mononuclear cells were isolated, and the amount of inﬁl-
trating CD45.2 expressing cells were analyzed. We could
show that more WT GMaM migrated toward the colonic
lamina propria compared with the WT control monocytes.
Interestingly, CD39/ GMaM did not show an augmented
migration toward the inﬂamed colon compared to WT and
CD39/ control monocytes (see Figure 8C). Hence, the
GMaM of CD39/ origin did migrate less efﬁciently to the
colon compared with the GMaM from WT origin. Thisny-stimulating factor–activated monocytes (GMaM) have
colitis in wild-type C57Bl/6 mice. (A) Chronic colitis induced
ay before the start of the third treatment cycle, mice received
as vehicle. Body weight was monitored daily and is shown as
nts with C57Bl/6 mice (n ¼ 7–15 per treatment group). (B) On
asured for each treatment group. Graphs show the mean ±
f colitis severity (MEICS) scores (mean ± SEM) based on high-
in 1b ¼ white bars, tumor necrosis factor a ¼ black bars) were
uantitative reverse-transcription polymerase chain reaction in
SEM for three independent experiments (n ¼ 11 per treatment
d by two blinded investigators and performed for the proximal
tative pictures of chronic colitis in C57Bl/6 mice on day 20 for
plaque; n ¼ 11 per treatment group). (G) Representative
rol mice are shown (H&E and CD11b staining; scale bar: 100
t t test except for body weight change where two-way analysis
< .01; ***P < .001.
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Figure 4. Granulocyte-macrophage colony-stimulating factor–activated monocytes (GMaM) inﬁltrate the intestine at
higher numbers and persist longer. (A) GMaM and control monocytes were stained for cell surface expression of gut homing
molecules and analyzed by ﬂow cytometry. Expression is shown as representative dot plots gated on CD11bþ cells showing
Ly6c expression (y axis) versus respective cell surface molecules (x axis). (B) GMaM and control monocytes were labeled with
1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide and injected intravenously at day 13 of chronic dextran sulfate
sodium–induced colitis. Monocyte inﬁltration in the intestine was visualized after 48 hours and 96 hours, and representative
pictures are shown (n ¼ 3). (C) After 96 hours, the intestine was removed and monocyte inﬁltration especially into Peyer’s
patches, visualized by ﬂuorescence reﬂectance imaging, was evaluated (arrow shows Peyer’s patches). (D) Mean ﬂuorescence
intensity (mean ± SEM) of Peyer’s patches is shown (n ¼ 5–7). Statistical signiﬁcance was determined by unpaired Student
t-test. *P < .05.
442 Weinhage et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4suggests and conﬁrms the role of CD39 in migration of
monocytes.
Finally, we asked whether a direct in vivo effect of CD39
on GMaM is responsible for Treg cell induction. To this end,
we injected CD39/ GMaM and WT responder T cells in
parallel into Rag1/ mice as described earlier (see
Figure 6C). However, in this setting we did not observe a
differential effect of CD39 as CD39/ GMaM were able to
induce Treg cells in the spleen of the recipient mice (see
Figure 8D).Discussion
Based on observations and reports in CD that showed
defects associated with innate immunity, it was hypothe-
sized that this arm of the immune system is central for thedevelopment of CD. Therefore, clinical studies were per-
formed using colony-stimulating factors (eg, GM-CSF) to
modulate innate immune cell functions. GM-CSF therapy
has been shown to ameliorate CD in some patient groups
and provides partial protection against intestinal inﬂam-
mation in a mouse DSS colitis model (reviewed in Däb-
ritz2). Because GM-CSF acts primarily on monocyte/
macrophages, here we have focused on the mechanisms by
which GMaM might exert their presumed therapeutic
action.
Phenotypically, GMaM did not ﬁt into current monocyte
subtype deﬁnitions dividing monocytes according to surface
markers and functions in classic/inﬂammatory, intermedi-
ate, and nonclassic monocytes.33 Markers for inﬂammatory
monocytes, such as costimulatory CD80 and proin-
ﬂammatory IL-1b, are up-regulated on GMaM but also
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Figure 5. Granulocyte-macrophage colony-stimulating factor–activated monocytes (GMaM) induce Foxp3D T cells in
dextran sulfate sodium (DSS)-induced colitis, and T cells mediate the beneﬁcial effect of GMaM. (A) Regulatory T cells
(Treg) were stained in wild-type (WT) mice treated with DSS (red frames) and control WT mice using a monoclonal antibody
raised against Foxp3. Examples of colonic lymph follicles harboring Treg are shown for each treatment group (scale bar: 50
mm). (B) The number of Foxp3þ cells in lymph follicles was quantiﬁed and is displayed as mean ± standard error of the mean
(SEM) of positive cells per mm2 (n ¼ 8–12). (C) Chronic colitis was induced by repeated oral administration of DSS in Rag1/
mice. Untreated Rag1/mice that received only plain water served as controls. One day before the start of the third treatment
cycle, mice received control monocytes, GMaM, or as a vehicle control phosphate-buffered saline alone, intravenously by the
tail vein. Body weight of Rag1/ mice was monitored and is shown as the percentage of weight change of two independent
experiments (n ¼ 6 per treatment group). (D) Colons were removed, and the colon lengths were measured for each treatment
group. Graphs show the mean ± SEM. Statistical signiﬁcance was determined by unpaired student’s t-test. *P < .05;
***P < .001.
July 2015 GM-CSF-Activated Monocytes Ameliorate DSS Colitis 443anti-inﬂammatory molecules like CD121b, IL-1Ra, and Arg1.
Furthermore, CX3CR1, CD163, and CD206 that are
described to be hallmarks of nonclassic monocytes are
down-regulated in GMaM. Because nonclassic monocytes
are known to give rise to M2-polarized macrophages,34,35 it
was noticeable that the M2 markers, FIZZ1 and YM1, were
both up-regulated. In summary, despite their phenotypicaldiversity, GMaM mainly seem to represent monocytes in a
developmental stage passaging toward M2-polarized
macrophages.
The distinct phenotype of GMaM likely reﬂects their
diverse functional properties. GMaM showed diminished
adhesion and phagocytosis, and increased production of
ROS needed for the killing of pathogens; but it also recently
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Figure 6. Granulocyte-macrophage colony-stimulating factor–activated monocytes (GMaM) showed beneﬁcial effects
in T-cell transfer colitis and led to increasing numbers of splenic regulatory T cells (Treg) in vivo. (A) T-cell transfer colitis
was induced by intravenous injection of T cells in Rag1/ mice. Monocyte transfer (intravenous) was performed when
mice had developed colitis symptoms between days 19 and 22. Body weight was monitored and is shown as the per-
centage of weight change (mean ± standard error of the mean [SEM]) of two independent experiments with Rag1/ mice
(n ¼ 6 per treatment group). (B) Weight of individual Rag1/ mice of different groups was measured before (days 0 to 21)
and after (days 21 to 31) monocyte transfer. (C) Rag1/ mice were simultaneously injected with CD4þ T cells and GMaM
or control monocytes. After 7 days, the spleens were removed, and the presence of Foxp3þ CD4þ T cells was evaluated
by ﬂow cytometry. Shown is the mean ± SEM of total Treg cells based on the number of splenocytes. Statistical
signiﬁcance was determined by (A) two-way or (C) one-way analysis of variance with Bonferroni correction. *P < .05;
**P < .01.
444 Weinhage et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4has been described to play a key role in the development of
M2-polarized macrophages.36 In addition, inﬂammatory NO
production was signiﬁcantly reduced while anti-
inﬂammatory arginase activity increased; thus, these cells
seemed to have a more anti-inﬂammatory status.
Because GMaM displayed an anti-inﬂammatory
phenotype, we asked whether these cells might confer
therapeutic beneﬁts in vivo. DSS-induced colitis has been
previously used to evaluate GM-CSF effects in the mouse,
and it provides a robust model through which mecha-
nisms of mucosal innate immunity and intestinal barrier
function can be dissected.9,11,13,37 We established a new
protocol that more closely resembles a chronic form of
DSS-induced colitis with typical clinical symptoms and
moderate weight loss but manifested barrier damage. The
adoptive transfer of GMaM into mice with established
chronic DSS-induced colitis displayed a beneﬁcial effect
on speciﬁc clinical parameters, including body weight,colon length, and MEICS scores as assessed by small an-
imal endoscopy.
GMaM treatment of mice with DSS-induced colitis
resulted in a reduced number of inﬂammatory cellular in-
ﬁltrates, and related production of proinﬂammatory cyto-
kines such as IL-1b and TNFa in the colon was dramatically
decreased. In addition, the signiﬁcant up-regulation of the
decoy receptor for IL-1 (CD121b) and IL-1Ra on GMaM
further supports the beneﬁcial effect of GMaM by seques-
tering colitis-associated IL-1b in the intestine of mice with
DSS-induced colitis.38 Moreover, GMaM displayed highly
selective gut homing activity, particularly targeting
lymphoid follicles (ie, Peyer’s patches), which is also re-
ﬂected by the increased expression of CCR2 and CCR6.
Furthermore, up-regulated CD39 might support migration
of GMaM as we found less migration toward inﬂamed
colonic lamina propria when we used CD39/ GMaM for
in vivo migration studies.
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carboxyﬂuorescein succinimidyl ester (CFSE)-labeled T cells were cocultured with respective monocytes (ratio 5:1, triplicates
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(n ¼ 5). (B) T cells were cocultured with GMaM or control monocytes at a ratio of 5:1 (T cells/monocytes). Cells were stained for
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Foxp3þ Treg, potentially indicative of an indirect immuno-
modulatory role of GMaM. In support of this notion,Brem-Exner et al9 showed that interferon-g–induced
macrophages could induce Foxp3þ Treg in vitro. Moreover,
we showed that naive T cells when cocultured with GMaM
446 Weinhage et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4were induced to proliferate and acquired a Foxp3þ Treg
phenotype in vitro.
Assessment of GMaM function in Rag1/ mice pro-
vided key evidence that functional T cell subsets and most
likely Treg are required for the immunomodulatory effects
of GMaM. More strikingly, the addition of T cells together
with GMaM into Rag1/ mice provided direct evidence of
GMaM’s capability to differentiate Foxp3þ Tregs also
in vivo. Therefore, GMaM can induce protective Treg
within the context of experimental colitis via direct0.0
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We have also examined possible mechanisms by which
GMaM may program naive T cells to a Treg phenotype.
Recent studies have shown that IL-10 produced by CD103þ
DCs or CX3CR1þ intestinal macrophages39,40 is required for
intestinal Treg induction and thus maintenance of gut ho-
meostasis.41 Indeed, in our study GMaM were shown to
release high levels of IL-10. However, IL-10 and IL-10 re-
ceptor blockade studies showed that IL-10 is not requiredCD45.2+
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conditions tested. In addition, CD39/ GMaM failed to
produce higher amounts of IL-10. Nevertheless elevated
numbers of splenic Treg were found in vivo when CD39/
GMaM and WT T cells were simultaneously injected into
Rag1/ mice. GMaM also produced high levels of proin-
ﬂammatory IL-6 and TNFa; the latter has been reported to
drive expansion of Treg.42 Again, by blocking with speciﬁc
antibodies we could rule out a role for TNFa in GMaM-
mediated Treg induction (data not shown).
Other molecules involved in Treg induction by antigen-
presenting cells are RA43 and arginase.30 We detected a
signiﬁcant down-regulation of the RA-converting enzyme
ALDH activity, necessary for RA production, in GMaM.
Therefore, it is very unlikely that GMaM reprogram naive T
cells into Treg by this mechanism. Another major inducer of
Treg is arginase, and we detected a signiﬁcant up-regulation
of Arg1 mRNA expression as well as increased Arg1 activity
in GMaM. Surprisingly, Treg did develop in cocultures with
GMaM even in the presence of Arg1 inhibition. As we also
found up-regulation of ectonucleotidases on GMaM, we
consequently investigated whether these molecular path-
ways could be involved in the observed Treg induction.
It is known that the proinﬂammatory danger signal ATP
can be processed by monocyte expressed E-NTPDase
(CD39), which catalyzes ATP and adenosine diphosphate to
adenosine monophosphate.44 In a further step, ecto-50-
nucleotidase (CD73) rapidly dephosphorylates adenosine
monophosphate into anti-inﬂammatory adenosine.45 Aden-
osine has been described to be of importance for regulatory
mechanisms in the immune system and in induction of
Treg.28 Because this pathway promotes an anti-
inﬂammatory milieu, its potential has already been recog-
nized and tested in the context of IBD. CD39-deﬁcient mice
consistently developed more severe DSS-induced colitis, and
CD39 somatic mutations have been found to be associated
with IBD.46
It has been described that CD39 and CD73 are jointly
up-regulated on M2-polarized macrophages47 and that
Treg express high numbers of these enzymes.48 We
therefore hypothesized that this could provide at least one
possible mechanism by which GMaM exert their anti-Figure 8. (See previous page). Functional characterization o
lating factor–activatedmonocytes (GMaM) in vitro and their m
GMaM were generated from CD39/ and corresponding wild-
functionswas evaluated. The ability to adhere to plastic surfaces a
oxygen species (ROS) production is presented as mean ﬂuoresc
measure the production of retinoic acid (RA), aldehyde dehyd
displayed as the percentage of Aldeﬂuor-positive cells (n ¼ 3). N
pernatants (n ¼ 3). (B) Cytokine secretion after lipopolysacchari
using a bead-based multiplex assay (n¼ 6). (C) Chronic colitis wa
the third dextran sulfate sodium (DSS) treatment cycle, the mice
monocytes, orCD39/GMaM (2 106/mouse). Two days after i
isolated, and inﬁltrating CD45.2 positive cells were stained and m
respective bar graph (mean ± standard error of the mean [SEM];
naive WT CD4þ T cells (2  106/mouse) and CD39/ GMaM o
removed after 7 days, and the presence of Foxp3þ CD4þ T cells w
total regulatory T-cells based on the number of total splenocytes.
variance with Bonferroni correction. *P < .05; **P < .01; ***P < .inﬂammatory function directly in the intestine by seques-
tering ATP, or by interaction with cells of the adaptive
immune system by providing adenosine. Until now, it was
thought that Treg form an autocrine loop using self-
generated adenosine that binds to Treg-expressed adeno-
sine receptors (eg, A2AR) resulting in Treg expansion and
higher Foxp3 expression.29,49 However, it remains un-
proven as to whether these activities degrading ATP to
adenosine could be provided by a second cell type that is
surrounding the cell, in our case the monocyte, with an
adenosine-rich “purinergic halo,” thereby modifying cells in
close proximity. We demonstrate that CD39 and CD73 have
a decisive impact on GMaM-induced Treg differentiation
in vitro, as Treg induction from naive T cells was indeed
dependent on CD39 and CD73 activity as well as on
adenosine provided by monocytes. However, because Treg
induction by GMaM is not completely blocked by inhibition
of CD39 and CD73, an as-yet-unidentiﬁed mechanism could
also contribute to Treg differentiation. This idea is sup-
ported by the ﬁnding that CD39/ GMaM, when added
together with WT T cells into Rag1/ mice also showed
the capability to differentiate Foxp3þ Tregs in vivo.
Nevertheless, in this setting it is possible that other host
cells such as monocytes/macrophages or CD39-expressing
epithelial cells could compensate for the lack of CD39 on
CD39/ GMaM. However, it remains to be shown and
needs future study, for example, by using CD39/ and
CD73/ as well as double-knockout T cells and/or
monocytes to dissect the in vivo role of CD39 on Treg cell
induction during inﬂammation.
Taken together, we have shown that GM-CSF induces a
speciﬁcally activated monocyte subset in mice that is char-
acterized by less pronounced ampliﬁcation of classic innate
immune mechanisms (important for their role in host de-
fense) and more induction of M2-polarized macrophage-
related immunomodulatory functions (important for their
cross-talk with adaptive immunity). The resulting monocyte
phenotype, which we have termed GMaM, has a protective
and therapeutic role in chronic DSS-induced colitis in mice.
The beneﬁcial effects of GMaM are at least in part attrib-
utable to their potency to modulate the T-cell compartment.
As a novel pathway involved in the interaction of innate andf CD39-deﬁcient granulocyte-macrophage colony-stimu-
igration in vivo.Bonemarrow-derived control monocytes and
type (WT) mice in vitro. (A) The inﬂuence of CD39 on GMaM
ndphagocytosis of pHrodo particles is shown (n¼ 3). Reactive
ent intensities of rhodamine positive cells (n ¼ 3). To indirectly
rogenase (ALDH) activity was measured using Aldeﬂuor and
itric oxide (NO) production was determined in cell culture su-
de (LPS) treatment was measured in cell culture supernatants
s induced using DSS in CD45.1 mice. One day before starting
received CD45.2 control monocytes, GMaM, CD39/ control
njection, lamina propria mononuclear cells from the colon were
easured by ﬂow cytometry. Shown is the gating strategy and
n ¼ 3–4). (D) Rag1/ mice were simultaneously injected with
r CD39/ control monocytes (2  106/mouse). Spleens were
as evaluated by ﬂow cytometry. Shown is the mean ± SEM of
Statistical signiﬁcancewas determined by one-way analysis of
001; n.s., not signiﬁcant.
448 Weinhage et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 4adaptive immunity, we propose that GMaM may act through
CD39 and CD73 to convert ATP to adenosine to induce
regulatory T cells from naive T cells.References
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Supplementary Table 1.Primer Sequences for Quantitative
Reverse Transcription Polymerase
Chain Reaction
Gene
Forward Primer
Sequence (50-30)
Reverse Primer
Sequence (50-30)
Arg1 CTC CAA GCC AAA GTC
CTT AGA G
GGA GCT GTC ATT AGG
GAC ATC A
CD121b GCA TCC CAC TGT GAG
CAA ATG
GCA AGT AGG AGA CAT
GAG GCA GAG
CD163 GTC TCT GAG GCT GAC
CAA CGA A
CAC AGT GGT TGG AGA
CAT ATT GCT
CD206 AGA CGA AAT CCC TGC
TAC TGA A
TAG AAA GGA ATC CAC
GCA GTC T
CD39 AAG GTG AAG AGA TTT
TGC TCC AA
TTT GTT CTG GGT CAG
TCC CAC
CD73 GGA CAT TTG ACC TCG
TCC AAT
GGG CAC TCG ACA CTT
GGT G
CD80 AAA TAT GGA GAT GCT
CAC GTG TCA G
CTG TTA TTA CTG CGC
CGA ATC C
CX3CR1 TCA TCA GCA TCG ACC
GGT ACC
TGA CAC CGT GCT GCA
CTG TC
FIZZ1 CCT GGA ACC TTT CCT
GAG ATT CTG
GAT GCA GAT GAG AAG
GGA ACA AGT
IL-1Ra TTT AGC TCA CCC ATG
GCT TCA G
CAG CAA TGA GCT GGT
TGT TTC TC
IL-1b TGT CTT GGC CGA GGA
CTA AGG
TGG GCT GGA CTG TTT
CTA ATG C
IRF4 CCG ACA GTG GTT GAT
CGA CC
CCT CAC GAT TGT AGT
CCT GCT T
RPL TGG TCC CTG CTG CTC
TCA AG
GGC CTT TTC CTT CCG
TTT CTC
TNFa AGA AAC ACA AGA TGC
TGG GAC AGT
CCT TTGCAG AAC TCA
GGAATG G
YM1 GGA GTA GAG ACC ATG
GCA CTG AAC
GAC TTG CGT GAC TAT
GAA GCA TTG
Supplementary Table 2.Antibodies for Flow Cytometry
Molecule Clone Manufacturer
B7H1 29E.2A3 Biolegend (San Diego, CA)
CCR2 475301 R&D Systems (Abington, UK)
CCR6 29–2L17 Biolegend
CD11b M1/70 Biolegend
CD121b 4E2 BD Bioscience (Heidelberg,
Germany)
CD39 24DMS1 eBioscience (San Diego, CA)
CD4 RM4–5 Biolegend
CD45.1 A20 Biolegend
CD45.2 104 Biolegend
CD73 TY/11.8 Biolegend
CD80 16–10A1 Biolegend
CD86 IT2.2 Biolegend
Foxp3 FJK-16s eBioscience
Ly6c HK1.4 Biolegend
MHCII (I-A/I-E) M5/114.15.2 eBioscience
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